PTHS Company Profile and Key Details

Pelthos Therapeutics Inc. generated EPS of $nan over the past year. Five-year average earnings growth is -87.88%. Analyst sentiment is bullish. Analyst rating data shows there are 6 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $66.00 to $48.00. The high target offers 163.68% upside. The low target suggests 91.77% downside. The mean target is $57.00. This offers 127.73% upside. Pelthos Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 134.75%. The prior quarter beat by -10.43%. Over the last six quarters, Apple has recorded several small beats. These include 73.55% in August 13, 2025.

Pelthos Therapeutics Inc. has 3.48 million shares outstanding. The public float is 1.39 million shares, elevated short interest at 4.12% of float. This equals 70.67 thousand shares. The short ratio is 2.28 days. Institutional investors hold 77.08% of the float. Insiders own 53.77%. Friedberg Ezra M holds 81.04 thousand shares, Davis Todd C has 75.33 thousand shares and Malamut Richard has 27.42 thousand shares. Over the past six months, insider transactions show net selling. They sold 3.06 thousand shares across 9 transactions.

PTHS has shown weak momentum, losing -12.52% over the past week and -22.93% over the past quarter, though year-to-date performance is down -27.9%. Short-term trend indicators are mixed aligned (SMA20 3.46%, SMA50 -3.75%, SMA200 0.16%). The stock’s 14-day RSI is 50.96 (neutral), while the ATR of 1.65 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -56.71% below its high and over 161.11% above its low. Average 10-day trading volume of 68.63 thousand shares is slightly above the 3-month average of 55.60 thousand, indicating heightened recent market interest.

Pelthos Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $30.49. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that Pelthos Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -8.99%, with price expected at $22.78 by September 16, 2026, within a range of $21.64 to $23.86 3-Month Outlook: Projected fall of -8.59%, reaching $22.88 by December 01, 2026, with a range of $22.19 to $23.57. 1-Year Outlook: Projected loss of -18.3%, with price at $20.45 by September 02, 2027, within a range of $19.04 to $21.96.

Pelthos Therapeutics Inc. (AMEX:PTHS) shares are down -27.9% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pelthos Therapeutics Inc. trading at a premium to the broader market with a P/E of -0.61. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $56.42, suggesting 125.41% upside. Our AI forecast model points to short-term weakness (-8.99% over two weeks), a medium-term fall (-8.59% over three months), and a longer-term loss (-18.3% over one year), with expected trading ranges indicating moderate volatility.

Pelthos Therapeutics Inc. (AMEX:PTHS) closed at $25.03 USD, gaining $0.21 (0.85%) from the previous close of $24.82. The stock is currently mid-range between its 52-week high and low $18.19 and $37.50. With a market capitalization of about $87.00 million, Pelthos Therapeutics Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.13). Key stats such as the average daily volume over the past year has been around 55.87 thousand shares, trading with heavier-than-usual volume. Headquartered in Durham, NC, Pelthos Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Scott Plesha, the company employs approximately 92 people and listed since February 16, 2024. Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs.

Pelthos Therapeutics Inc. trades at a P/E ratio of -0.61, slightly below the S&P 500 average, with a price-to-sales ratio of 2.04 and a price-to-book ratio of -59.92 indicating negative book value, which may reflect financial stress. The P/FCF stands at -2.07, also below market averages.